ABSTRACT
In this study, ultra performance liquid chromatography-quadrupole-time of flight mass spectrometer-MSE (UPLC-Q-TOF-MSE) combined with UNIFI analysis platform was used to rapidly analyze and identify the metabolites of hederagenins 3-O-α-L-rhamnosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-α-L-arabopyranoside (Pulsatilla saponin D) and oleanolic acid 3-O-α-L-rhamnosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-α-L-arabopyranoside (Pulsatilla saponin B7) and hederagenins 3-O-α-L-rhamnosyl-(1→2)-α-L-arabopyranoside (Pulsatilla saponin BD) in plasma and colonic tissue of normal and ulcerative colitis (UC) rats. The database and analysis methods were established based on the precise molecular weight of compounds, retention time, neutral loss and reported data, and then the final data were obtained by comparing with the blank control group, combining with the deviation and the cracking rule of the compound. The results showed that the glucoses, hydroxylation and dehydroxylation, methylation and demethylation, dehydrogenation, decarboxylation and hydrolysis of saponin D, B7 and BD occurred in the plasma and colon tissues of normal and UC model rats. This study will clarify the metabolic transformation of Pulsatilla saponins D, B7 and BD in rats, determine the prototype components and their metabolites that enter the body, and whether colon injury will affect their metabolism in vivo, so as to explore the possible anti-colitis effective components in the prototype or metabolites of Pulsatilla saponins D, B7 and BD. This experiment was approved by Animal Ethics Committee of Jiangxi Science and Technology Normal University (approval number: Y202227).
ABSTRACT
Objective To investigate the significance of serum HbA1c and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute coronary syndromes. Methods 120 patients with acute coronary syndromes were enrolled in Jinhua Wenrong hospital from June 2015 to December 2016. Among them, 68 patients with diabetes mellitus (group A) and 52 patients without diabetes (group B) were selected. 80 healthy cases in this hospital were selected as the control group. (HbA1c) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured and compared. Results The level of serum HbA1c in group A was (9.52±1.57)%, which was significantly higher than that in group B (5.92±0.36)%, control group (5.82±0.41)%, t=(16.19, 20.29), P=(0.00, 0.00); And group B compared with the control group, t=1.43, P=0.15. The level of NT-proBNP in group A was (442.78±79.14) μg/mL, which was significantly higher than that in group B (221.45±33.89) μg/mL, control group (87.14±14.82) μg/mL, t=(18.87, 39.41), P= (0.00, 0.00); and group B was significantly higher than those in the control group, t=31.19, P=0.00. Cardiac function in patients with acute coronary syndromes was positively correlated with serum HbA1c and NT-proBNP (r=0.624, 0.582). Conclusion The levels of HbA1c and NT-proBNP in patients with acute coronary syndromes were significantly higher than those in patients with acute coronary syndromes. The levels of HbA1c and NT-proBNP in patients with acute coronary syndromes were helpful to evaluate their cardiac function.
ABSTRACT
Objective To investigate the significance of serum HbA1c and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute coronary syndromes. Methods 120 patients with acute coronary syndromes were enrolled in Jinhua Wenrong hospital from June 2015 to December 2016. Among them, 68 patients with diabetes mellitus (group A) and 52 patients without diabetes (group B) were selected. 80 healthy cases in this hospital were selected as the control group. (HbA1c) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured and compared. Results The level of serum HbA1c in group A was (9.52±1.57)%, which was significantly higher than that in group B (5.92±0.36)%, control group (5.82±0.41)%, t=(16.19, 20.29), P=(0.00, 0.00); And group B compared with the control group, t=1.43, P=0.15. The level of NT-proBNP in group A was (442.78±79.14) μg/mL, which was significantly higher than that in group B (221.45±33.89) μg/mL, control group (87.14±14.82) μg/mL, t=(18.87, 39.41), P= (0.00, 0.00); and group B was significantly higher than those in the control group, t=31.19, P=0.00. Cardiac function in patients with acute coronary syndromes was positively correlated with serum HbA1c and NT-proBNP (r=0.624, 0.582). Conclusion The levels of HbA1c and NT-proBNP in patients with acute coronary syndromes were significantly higher than those in patients with acute coronary syndromes. The levels of HbA1c and NT-proBNP in patients with acute coronary syndromes were helpful to evaluate their cardiac function.